SCHEMBL4778151

SCHEMBL4778151

NC1CCN(c2ccc(-n3cnnn3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.50
MAPT P10636 2/20 0.50
F2 P00734 1/20 0.50
ALDH1A1 P00352 5/20 0.48
HPGD P15428 2/20 0.48
KCNJ1 P48048 2/20 0.47
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
KDM4E B2RXH2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TSHR P16473 1/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.43
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
USP2 O75604 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18519660 0.78 ALDH1A1 (0.50) MAPTALDH1A1HPGDKCNJ1HTT
SCHEMBL12615985 0.76 NOTUM (0.78) NOTUMMAPTF2ALDH1A1HPGD
SCHEMBL19783877 0.73 NOTUM (0.56) NOTUMMAPTF2ALDH1A1HPGD
SCHEMBL2263367 0.71 GPR119 (0.55) MAPTF2ALDH1A1HPGDHTT
SCHEMBL3441371 0.71 MAPT (0.57) MAPTALDH1A1HTTLMNATDP1
SCHEMBL1163779 0.71 NOTUM (0.64) NOTUMMAPTF2ALDH1A1HPGD
Hydrochloric Acid SCHEMBL6139934 0.70 GPR119 (0.53) MAPTF2ALDH1A1HTTL3MBTL1
SCHEMBL29717236 0.70 NOTUM (0.51) NOTUMMAPTALDH1A1HTTLMNA
SCHEMBL3060190 0.70 HTR3E (0.53) NOTUMMAPTALDH1A1HPGDHTT
SCHEMBL8724123 0.70 ADRB1 (0.53) MAPTALDH1A1L3MBTL1DPP4USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
EP-1220842-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2002-07-10 EP disclosed
WO-2001025200-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 NOTUM 2433/4885MAPT 4492/4885F2 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.